Drug profile · INN
tolebrutinib
CENRIFKI
tolebrutinib (CENRIFKI) is a tyrosine-protein kinase btk inhibitor.
EMA: unknown
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — tolebrutinib
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
tolebrutinib (CENRIFKI) is a tyrosine-protein kinase btk inhibitor.
Key facts
INN tolebrutinib
Brand CENRIFKI
Mechanism Tyrosine-protein kinase BTK inhibitor
Target Tyrosine-protein kinase BTK
Mechanism of action
Tyrosine-protein kinase BTK inhibitor
Primary target: Tyrosine-protein kinase BTK
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tolebrutinib?
tolebrutinib (CENRIFKI) is a tyrosine-protein kinase btk inhibitor.
What is the brand name for tolebrutinib?
CENRIFKI is a marketed brand name for tolebrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.